Figure 6

Sensitivity analysis for cost per life year saved (LYS). Sensitivity analysis findings are shown for cost-effectiveness ratios relative to no intervention for selected test technologies (VIA/VILI and careHPV@0.5 pg/ml) and screening strategies (once-lifetime and IARC-recommended intervals); similar results were obtained for other screening strategies. In general, the cost-effectiveness findings were most sensitive to assumptions about the progression rate from CIN3 to invasive cervical cancer, the discount rate, mortality to incidence ratio, the cost of careHPV testing and VIA, test accuracy and cancer treatment costs. The baseline values and range for sensitivity analysis are provided in Table 1.